On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- What is rotavirus?
- Global burden
- Pathogenesis
- Clinical manifestations
- Immune response to rotavirus infection
- Current licensed vaccines
- Rotavirus vaccines
- Efficacy / effectiveness
- Global vaccination programs
- Need for new more effective vaccines
- Rotavirus vaccine approaches
- Advantage of neonatal vaccination
- Rotavirus vaccines in development
- Vaccines in Phase 3 Human Trials
- UK BRV hexavalent
- RV3-BB live rotavirus vaccine (1)
- RV3-BB live rotavirus vaccine (2)
- Trivalent rotavirus P2-VP8 subunit vaccine
- Vaccines in Phase 1 Human Trials
- MT-5625
- Inactivated rotavirus vaccine
- Inactivated rotavirus vaccine CDC-9
- Vaccines in Preclinical Trial
- mRNA VP8 (Curevac)
- VLP vaccines
- VP4 (Xiamen University/Innovax, China)
- Human challenge model
- Human intestinal enteroids
- Summary
- Thank you
Topics Covered
- Rotavirus pathogenesis
- Rotavirus clinical manifestations
- Rotavirus vaccines
- Subunit vaccines
- mRNA vaccines
- Virus like particle (VLP) vaccines
- Neonatally administered live-attenuated vaccines
- Rotarix
- Human challenge model
Links
Categories:
Therapeutic Areas:
Talk Citation
Flanagan, K. (2025, March 31). Future potential for new and improved rotavirus vaccines [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/KCIZ5444.Export Citation (RIS)
Publication History
- Published on March 31, 2025
Financial Disclosures
- Prof. Katie Flanagan has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Microbiology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is
Katie Flanagan.
I'm an infectious
diseases specialist and
vaccinologist based
in Australia.
I'm going to talk about
rotavirus vaccines today.
0:13
Rotavirus are wheel-like particles
of the Reoviridae family.
They are large viruses,
approximately 100
nanometers in diameter.
They're non-enveloped
double-stranded RNA.
The double-stranded
RNA encodes for
six structural proteins and
six non-structural proteins.
There are three serotypes that
cause disease in
humans: A, B, and C.
But most of the human
cases are serotype A.
It's a very highly
contagious infection which
is transmitted
fecal-orally, generally,
but also via fomites.
0:51
Rotavirus causes a huge
global burden of disease with
over 125 million cases
occurring annually,
and nearly all children
would have been infected by
rotavirus by the
age of five years.
Rotavirus causes
approximately 40% of
the diarrheal
hospitalizations and
around 200,000 people will die
every year from infection.
If you look at the map,
you can see that the burden of
the disease is particularly in
Sub-Saharan Africa,
India, and Indonesia.
1:27
Rotavirus causes diarrhea
via a number of mechanisms.
Rotavirus invades
the small intestinal
gut mucosa by
entering into the mature
enterocytes either
at the mid or the upper
part of the villi,
as you can see on the diagram
on the right-hand side.
The diarrhea then
will be caused by
malabsorption, in particular,
where the villi have become
stunted and shortened and
they're unable to
absorb that well.
They also get destroyed.
There are a lot of
pro-inflammatory cytokines such as
nitric oxide and other
pro-inflammatory mediators.
There's an inhibition of
the uptake of fluid
and electrolytes.
There's also a secretory component
leading to osmotic diarrhea.
The villi become ischemic,
and the other mechanism
of diarrhea is by
increased motility of
the intestines due to
the activation of the
enteric nervous system.
You can see all of those factors
occurring in the diagram.
One of the viral
proteins, NSP 4,
acts directly as an
enterotoxin as well.